Patent ID: 8703137
Filing Date: 2014-04-22
Classification: A61P,C07K

Abstract:
1. A method of inhibiting tau polymerization in vivo, comprising administering to a human in need of therapy for Alzheimer's disease or other tauopathies an effective amount of free end-specific antibodies capable of selectively binding abnormal forms of tau proteins, said antibodies showing no reactivity and/or binding with a normal tau protein, and being administered under conditions and in an amount(s) effective to inhibit polymerization of tau in the brain of the human, wherein the abnormal forms of tau proteins are selected from the group consisting of hTau40 truncated at its C-terminus at the glutamic acid residue Glu391, hTau40 truncated at the aspartic acid residue Asp421, hTau40 truncated at its N-terminus at the aspartic acid residue Asp13, proteins homologous to hTau40 truncated at its C-terminus at the glutamic acid residue Glu391, proteins homologous to hTau40 truncated at the aspartic acid residue Asp421, and proteins homologous to hTau40 truncated at its N-terminus at the aspartic acid residue Asp13, the normal tau protein is a full length untruncated hTau40, and the antibodies specifically recognize a sequence out of SEQ ID NOs. 7-94 or 116 in a truncated hTau40 and bind the recognized sequence with equilibrium constant KD of from 1×10